{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:00:40Z","timestamp":1793448040028,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.annonc.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:19:11Z","timestamp":1759990751000},"page":"1433-1446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"H.J.","family":"Burstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-2118","authenticated-orcid":false,"given":"M.","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"S.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Thurlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meteb","family":"Al-Foheidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bago-Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Clement","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisse Bretel","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Joao","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheenah","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"de Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Demichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Fastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana Enrica","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebatallah Gamal","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Bahadir","family":"Gulluoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Kaidar-Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kaklamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kauer-Dorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusheel","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Isabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Saura","family":"Manich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Senkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Solbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Tausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cicero","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Villarreal-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jeanne","family":"Vrancken Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.09.007_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2025.09.007_bib3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.09.007_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.09.007_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of Germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.007_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110710","article-title":"Breast cancer outcomes after skin- and nipple-sparing mastectomy in BRCA pathogenic mutation carriers versus non-BRCA carriers","volume":"205","author":"Moshe","year":"2025","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.007_bib7","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1245\/s10434-022-13006-w","article-title":"Oncologic safety of nipple-sparing mastectomy for breast cancer in BRCA gene mutation carriers: outcomes at 70 months median follow-up","volume":"30","author":"Webster","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.007_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.annonc.2025.09.007_bib9","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jama.2024.26698","article-title":"Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial","volume":"333","author":"Hwang","year":"2025","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.annonc.2025.09.007_bib11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.007_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae040","article-title":"Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis","volume":"8","author":"Rajan","year":"2024","journal-title":"BJS Open"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.007_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/bjs\/znac411","article-title":"Medical and surgical postoperative complications after breast conservation versus mastectomy in older women with breast cancer: Swedish population-based register study of 34 139 women","volume":"110","author":"de Boniface","year":"2023","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.007_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae042","article-title":"Health-related quality of life by type of breast surgery in women with primary breast cancer: prospective longitudinal cohort study","volume":"8","author":"Gulis","year":"2024","journal-title":"BJS Open"},{"key":"10.1016\/j.annonc.2025.09.007_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-043015-075227","article-title":"Why are there so many mastectomies in the United States?","volume":"68","author":"Mamtani","year":"2017","journal-title":"Annu Rev Med"},{"issue":"17","key":"10.1016\/j.annonc.2025.09.007_bib16","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1200\/JCO.22.02553","article-title":"Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance)","volume":"41","author":"Boughey","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.007_bib17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.007_bib18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer - primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMe2414899","article-title":"Sentinel-lymph-node biopsy in early-stage breast cancer - is it obsolete?","volume":"392","author":"Morrow","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.annonc.2025.09.007_bib22","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.007_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/bjs.10791","article-title":"Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast","volume":"105","author":"Morrow","year":"2018","journal-title":"Br J Surg"},{"issue":"14","key":"10.1016\/j.annonc.2025.09.007_bib24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.007_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","article-title":"Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy","volume":"10","author":"Montagna","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.007_bib26","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","article-title":"Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: results from > 1500 patients on the I-SPY2 clinical trial","volume":"32","author":"Boughey","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35610","article-title":"Combined analysis of the MF18-02\/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided","volume":"131","author":"Muslumanoglu","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2025.09.007_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104411","article-title":"Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol","volume":"80","author":"van Hemert","year":"2025","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.007_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.24.01052","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study","volume":"43","author":"Montagna","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.007_bib31","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.prro.2023.12.015","article-title":"In regard to Shaitelman et al","volume":"14","author":"Kaidar-Person","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.annonc.2025.09.007_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104523","article-title":"Partial breast irradiation after sentinel lymph node biopsy omission: is it a valid alternative to whole breast Irradiation? Analysis of the dose to the sentinel lymph node region during whole breast irradiation vs. partial breast irradiation","volume":"82","author":"Behzadi","year":"2025","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.007_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.23.02270","article-title":"Omission of radiotherapy after breast-conserving surgery for women with breast cancer with low clinical and genomic risk: 5-year outcomes of IDEA","volume":"42","author":"Jagsi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.007_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer","volume":"388","author":"Kunkler","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.007_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","article-title":"Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial","volume":"16","author":"Kunkler","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2025.09.007_bib36","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial","volume":"26","author":"Meattini","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.007_bib38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jamaoncol.2024.2652","article-title":"Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical trial","volume":"10","author":"Wong","year":"2024","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2025.09.007_bib39","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2025.09.007_bib40","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib41","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"13","key":"10.1016\/j.annonc.2025.09.007_bib43","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant atezolizumab for early triple-negative breast cancer: the ALEXANDRA\/IMpassion030 randomized clinical trial","volume":"333","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2025.09.007_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/10781552251333650","article-title":"Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease","author":"Boucher","year":"2025","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.007_bib45","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.007_bib46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.007_bib47","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2025.09.007_bib49","article-title":"De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial","volume":"43","author":"Gao","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.007_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"issue":"9938","key":"10.1016\/j.annonc.2025.09.007_bib51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.007_bib52","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib53","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdi370","article-title":"Patients\u2019 preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?","volume":"16","author":"Duric","year":"2005","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2025.09.007_bib54","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2002.11.101","article-title":"Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less","volume":"20","author":"Fisher","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib55","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.007_bib56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2104162","article-title":"Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer","volume":"385","author":"Gnant","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.09.007_bib57","article-title":"15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS","volume":"43","author":"Francis","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.007_bib59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2025.09.007_bib60","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.09.007_bib61","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/cncr.34127","article-title":"Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: a National Cancer Database analysis","volume":"128","author":"Weiser","year":"2022","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","article-title":"Pathologic complete response (pCR) rates for patients with HR+\/HER2\u2212 high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial","volume":"36","author":"Huppert","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.09.007_bib63","article-title":"Extended endocrine therapy after 5 years of adjuvant LHRH-agonist in premenopausal patients with node-positive hormone receptor (HR)-positive early breast cancer","author":"Valenza","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10384","key":"10.1016\/j.annonc.2025.09.007_bib64","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2025.09.007_bib65","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1200\/JCO.23.01428","article-title":"Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology])","volume":"42","author":"Geyer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.007_bib68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib70","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.007_bib71","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","article-title":"Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial","volume":"36","author":"Wapnir","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.007_bib72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamaoncol.2019.4320","article-title":"Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: the NRG oncology\/RTOG 1014 phase 2 clinical trial","volume":"6","author":"Arthur","year":"2020","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2025.09.007_bib73","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1245\/s10434-024-16133-8","article-title":"Management of ipsilateral breast tumor recurrence following breast conservation surgery for ductal carcinoma in situ: a data-poor zone","volume":"31","author":"Diskin","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.09.007_bib74","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.21.02006","article-title":"Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108)","volume":"40","author":"Khan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2025.09.007_bib75","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.007_bib76","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ijrobp.2024.10.030","article-title":"Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): a multicenter, randomized phase 2 trial","volume":"121","author":"Reddy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.007_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jamaoncol.2025.0001","article-title":"Efficacy of hand cooling and compression in preventing taxane-induced neuropathy: the POLAR randomized clinical trial","volume":"11","author":"Michel","year":"2025","journal-title":"JAMA Oncol"},{"issue":"10476","key":"10.1016\/j.annonc.2025.09.007_bib78","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(24)02715-6","article-title":"Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial","volume":"405","author":"Dunn","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.007_bib79","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ogc.2024.03.003","article-title":"Cancer and female sexual function","volume":"51","author":"Falk","year":"2024","journal-title":"Obstet Gynecol Clin North Am"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425047180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425047180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:52:52Z","timestamp":1773870772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425047180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0923753425047180"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.007","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}